Status:

COMPLETED

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients

Lead Sponsor:

AstraZeneca

Conditions:

Asthma

Eligibility:

All Genders

16+ years

Phase:

PHASE3

Brief Summary

The primary objective of this study is to confirm the efficacy (superiority) of Symbicort® Turbuhaler® 160/4.5 µg twice daily for 8 weeks in comparison to Pulmicort® Turbuhaler® 200 µg twice daily + T...

Eligibility Criteria

Inclusion

  • Diagnosis of asthma with a documented history of at least 6 months duration prior to Visit 1
  • Prescribed daily use of an IGCS for \>=12 weeks prior to Visit 1. The dose of IGCS must be 400 to 800 µg/day of Pulmicort® Turbuhaler® or corresponding dose of IGCS. The prescribed dose of IGCS should be constant for at least 4 weeks prior to Visit 1
  • Prescribed daily use of sustained release theophylline for at least 8 weeks prior to Visit 1, or confirmed steady-state blood theophylline concentrations within the effective range (5-15 µg/mL) during 8 weeks prior to Visit 1. The prescribed dose of theophylline should be constant (400 mg/day) for at least 4 weeks prior to Visit 1

Exclusion

  • Any significant disease or disorder that may jeopardize the safety of the patient
  • Respiratory infection, judged by the investigator(s) as an infection affecting the asthma, within 4 weeks prior to Visit 1
  • Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1
  • Additional inclusion and exclusion criteria will be evaluated by the Investigator

Key Trial Info

Start Date :

October 1 2005

Trial Type :

INTERVENTIONAL

End Date :

November 1 2006

Estimated Enrollment :

340 Patients enrolled

Trial Details

Trial ID

NCT00252785

Start Date

October 1 2005

End Date

November 1 2006

Last Update

January 24 2011

Active Locations (43)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (43 locations)

1

Research Site

Komaki, Aichi-ken, Japan

2

Research Site

Seto, Aichi-ken, Japan

3

Research Site

Asahi, Chiba, Japan

4

Research Site

Noda, Chiba, Japan

Efficacy & Safety of Symbicort® TURBUHALER® 160/4.5 µg Twice Daily & Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily in Japanese Asthmatic Patients | DecenTrialz